Compare Taskus Inc (TASK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs TransMedics Group Inc — how do they compare? Taskus Inc trades at $7.99 (market cap $723.41M), while TransMedics Group Inc trades at $79.01 (market cap $2.81B). The key difference: TransMedics Group Inc is far larger — about 3.9× Taskus Inc's market cap, and Taskus Inc is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Taskus Inc for 34 Days and TransMedics Group Inc for 24 Days on average.
| TASK | TMDX | |
|---|---|---|
Market Cap | $723.41M | $2.81B |
Volume | 201,303 | 962,415 |
Sector | Technology | Health |
52-Week High | $14.69 | $150.42 |
52-Week Low | $4.57 | $61.99 |
Typical Hold Time | 34 Days | 24 Days |
Enterprise Value | $1.09B | $3.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs trades at $8.01, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company demonstrates strong fundamentals with revenue growth to $1.18B in 2025 and net income margin expansion to 8.75%. Recent Q2 2026 earnings beat expectations with $0.33 EPS versus $0.29 expected, driven by AI services growth offsetting Trust & Safety declines.
The stock appears undervalued with P/E of 6.8 and P/S of 0.6, supported by analyst consensus target of $9.33 representing 16% upside. Key risks include labor cost pressures and client concentration, while AI segment growth at 26% provides upside catalyst. Institutional ownership increased with Dimensional Fund Advisors raising stake by 12.8% in Q1 2026.
TransMedics Group (TMDX) trades at $81.07, up 0.98% on the day, but remains in a technical downtrend with a bearish moving average signal. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying but also multiple legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 analyst target but faces near-term headwinds from earnings misses and legal overhangs. Key risks include execution pressure from heavy investments and ongoing legal scrutiny, while the core organ transplant technology business maintains a growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
